logo
Plus   Neg
Share
Email

Gainers & Losers Of The Day: PULM, AQB, GALE, PETX, KTOV...

pharma-feb6-020617.jpg

The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of February 6, 2017.

GAINERS

1. Pulmatrix Inc. (PULM)

Gained 29.02% to close Monday's (Feb.6th) trading at $4.98.

News: No news

Read the report "Company Spotlight: Pulmatrix" that was posted on February 3, 2017 to know more about PULM.

2. AquaBounty Technologies Inc. (AQB)

Gained 19.85% to close Monday's trading at $15.76.

News: No news

Shares of AquaBounty underwent a 1-for-30 reverse share split on January 5, 2017 and were uplisted to the Nasdaq on January 19, 2017.

As you may know, AquaBounty is involved in developing AquAdvantage Salmon, a genetically engineered Atlantic salmon. AquAdvantage Salmon was approved by the FDA in November 2015.

AquaBounty is a majority-owned subsidiary of Intrexon Corp. (XON).

3. Galena Biopharma Inc. (GALE)

Gained 17.50% to close Monday's trading at $1.41.

News: The Data Safety Monitoring Board has recommended that two NeuVax clinical trials in combination with Herceptin be continued, following a futility assessment.

Last June, an Independent Data Monitoring Committee stopped a phase III trial of breast cancer vaccine NeuVax, dubbed PRESENT, for futility, which meant that the possibility of getting a positive result was remote.

In light of the early termination of the PRESENT trial, the independent Data Safety Monitoring Board performed separate futility assessments on a phase IIb trial of NeuVax in combination with Herceptin in node positive and triple negative HER2 IHC 1+/2+, and a phase II trial of NeuVax in combination with Herceptin in high risk, node positive or negative HER2 IHC 3+ patients.

This time around, the recommendations from the Data Safety Monitoring Board for NeuVax in combination with Herceptin are positive as there were no safety concerns and the studies were not deemed futile, according to the company.

4. Conatus Pharmaceuticals Inc. (CNAT)

Gained 17.01% to close Monday's trading at $5.09.

News: The company is all set to provide an overview of its programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 2:30 p.m. ET on Monday, February 13, 2017.

Near-term catalysts:

The company's lead compound is Emricasan, for the treatment of patients with chronic liver disease.

A phase IIb trial of Emricasan in NASH cirrhosis patients, dubbed ENCORE-LF, is expected to be initiated in the second half of this year.

Top-line data from an ongoing phase IIb trial of Emricasan in reducing hepatic venous pressure gradient in patients with compensated or early decompensated liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), and severe portal hypertension, dubbed ENCORE-PH, are expected to be reported next year.

Top-line data from a phase IIb clinical trial of Emricasan evaluating potential improvements in fibrosis and steatohepatitis in patients with fibrosis caused by NASH, dubbed ENCORE-NF, are also expected next year.

5. Galectin Therapeutics Inc. (GALT)

Gained 10.58% to close Monday's trading at $1.15.

News: The company is slated to present a report "The combination of immunotherapy plus galectin-3 inhibition with GR-MD-02 improves anti-tumor immunity and survival: Insights from mice and a first-in-human phase I clinical trial" on February 7, 2017 at the GTCBio 9th Immunotherapeutics & Immunomonitoring Conference.

A phase Ib trial of Galectin's GR-MD-02 in combination with Merck's (MRK) Keytruda in patients with advanced refractory metastatic melanoma and a phase Ib study of GR-MD-02 in combination with Bristol-Myers Squibb'S (BMY) Yervoy in patients with malignant melanoma are underway.

Preliminary data from the trials will be presented at the conference.

LOSERS

1. Aratana Therapeutics Inc. (PETX)

Lost 17.93% to close Monday's trading at $6.59

News: The launch of the company's ENTYCE, the first FDA-approved therapeutic specifically designed to stimulate appetite in dogs, originally scheduled for this month, is not going to happen until late-2017.

The reason for the delayed launch is due to the FDA's Center for Veterinary Medicine requesting additional information in connection with the company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at commercial scale.

2. Kitov Pharmaceuticals Holdings Ltd (KTOV)

Lost 11.46% to close Monday's trading at $2.55. In after-hours, the stock fell another 40% to $1.53.

News: On February 6, 2017, the Israeli publication Calcalist reported that Kitov's Chief Executive Officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority on suspicion of publishing misleading information in connection with a recent clinical trial of one of Kitov's products. (Sources: Pomerantz Law Firm and Rosen Law Firm).

The company's key drug candidate is KIT-302, a combination drug to treat osteoarthritis pain and hypertension simultaneously. The preparation of the NDA for KIT-302 to be submitted to the FDA is underway, and is expected to be completed within the first quarter of 2017.

3. Moleculin Biotech Inc. (MBRX)

Lost 11.11% to close Monday's trading at $2.00.

News: No news

Near-term catalyst: Report data from phase II trial evaluating Annamycin as a potential treatment for relapsed or refractory acute myeloid leukemia by the second half of 2017.

4. Haemonetics Corp. (HAE)

Lost 8.08% to close Monday's trading at $38.00

News: Financial results for the third quarter ended December 31, 2016 reported.

Third quarter fiscal 2017 revenue was $227.8 million, down 2% compared to the year-ago quarter.

The company posted a net income of $15.4 million or $0.30 per share in the third quarter of fiscal 2017 compared with a net loss of $59.4 million or $1.17 per share in the year-ago quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>